Our Science
Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Drug-Na?ve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED Study)
2020 ADA Poster
Online link unavailable, presentation available upon request. (BD@huamedicine.com)
Focus Us
Copyright ? 2024 Hua Medicine (Shanghai) Co., Ltd. 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號(hào): （滬）-非經(jīng)營(yíng)-2022-0079
滬ICP備14036654號(hào)-1
滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use
滬ICP備14036654號(hào)-1
滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x